Shaolin Capital Management’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-400,000
Closed -$4.18M 941
2023
Q1
$4.18M Sell
400,000
-153,047
-28% -$1.59M 0.12% 148
2022
Q4
$5.65M Buy
553,047
+173,745
+46% +$1.76M 0.17% 172
2022
Q3
$3.81M Buy
379,302
+172,740
+84% +$1.73M 0.11% 269
2022
Q2
$2.05M Sell
206,562
-43,438
-17% -$431K 0.05% 396
2022
Q1
$2.47M Buy
+250,000
New +$2.47M 0.06% 370

Other funds holding BIOS

Shaolin Capital Management's BIOS Position: Q2 2023 in Review

Shaolin Capital Management sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2023, closing a stake of 400,000 shares — an estimated $4.18M sold.

Shaolin Capital Management first reported a position in BIOS in Q1 2022 and held it in 5 quarters. The position peaked at $5.65M in Q4 2022. 32 funds tracked by Wall St. Rank hold BIOS as of Q2 2023.

  • Shaolin Capital Management reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Shaolin Capital Management sold 400,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2023, an estimated $4.18M.
  • Shaolin Capital Management first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 5 quarters.
  • Shaolin Capital Management's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $5.65M in Q4 2022.
  • 32 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2023.

Based on Shaolin Capital Management's 13F filing for Q2 2023, filed 15 Aug 2023.